Prime Medicine Reports First Quarter 2026 Financial Results and Provides Business Updates
Prime Medicine reported Q1 2026 net loss of $49.1 million with $149.2 million in cash, extending its runway into 2027. The company remains on track to file IND/CTA applications for PM577 in Wilson Disease and PM647 in AATD in 2026, with initial clinical data expected in 2027, while it continues BLA dialogue for PM359 in CGD.
Key figures
- Revenue
- 856000
- Revenue Yoy
- -41.1%
- Net loss
- 49100000
- Cash runway
- into 2027
- Ga expenses
- 17400000
- Rd expenses
- 34100000
- Cash position
- 149200000
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.